Key Takeaways
- Partnership phasing drove the quarter, not structural damage: Q4 partnership revenue fell to INR 153 cr from ~INR 200 cr in Q3, driven by stock stabilization, frozen periods on new contracts, and institutional pricing headwinds. Management calls the full-year trend stabilizing at minus 2% and expects the partnership to grow, but warns fluctuations will persist through 2026.
- Diabetes portfolio held its ground despite GLP-1 pressure: Lantus maintained 31% basal market leadership with volume acceleration of plus 6%, while Toujeo and Soliqua grew double digits. The analog market got a tailwind from Novo Nordisk discontinuing human insulin pens.
- No new products in 2026, so growth must come from within: Management confirmed zero new product launches for Sanofi India this year. The growth case rests on Soliqua's expansion into the public sector, Toujeo's public-sector push, and partnership stabilization.
- Margins compressed to an 8-quarter low, and management won't break out the drivers: EBITDA margin hit 21.5%, with operating expenses down 17% but partnership revenue drop and other operating income decline weighing on the P&L. Management declined to disclose segment-level margins.
- What to watch next quarter: Whether the partnership revenue fluctuation narrows or widens, any early signal on Soliqua's public-sector traction, and the final dividend quantum approved at the May/June general assembly.
Partnership Transition: The Quarter's Dominant Swing Factor
- Q4 drop mechanics: Partnership sales fell to INR 153 cr from ~INR 200 cr in Q3 because of stock stabilization and replenishment phasing, a frozen period entering the new OAD partnership with Emcure, additional gross-to-net charges on OADs, and aggressive competition discount in certain institutional accounts.
- Full-year picture is less alarming: For the full year, the partnership is stabilizing at minus 2%. Secondary data shows partners are delivering per agreement, and management says taking out one-off inventory impacts, the partnership is growing as expected.
- End-market growth by portfolio: The CV portfolio with Cipla grew low single digits, hurt by competition discount turbulence in the first two quarters. The OAD portfolio with Emcure grew higher single digits, better than the first half. Overall, partnered products grew single digits at a lower rate.
- Pricing mechanism disclosed in part: For NLEM products, growth equals volume growth plus WPI-linked inflation on the supply price. For non-NLEM products, partners can increase prices up to 10% in line with MRP increases. Management did not disclose the specific contractual pricing structure.
- Institutional headwind: Aggressive competition discount in certain institutional business accounts created a headwind. Management says it is trying to tackle this with an innovative access model as it enters 2026.
- Fluctuation is not over: Management declined to give a base partnership number for 2026 comparison and warned that fluctuation will continue through 2026, with stabilization expected only by year-end due to stock replenishment agreements that systematically create quarter-to-quarter swings.
Rachid Ayari: "The fact that we are not giving any forward-looking, but I think the fluctuation will continue in 2026. I think by end of 2026, we will stabilize this partnership because, as mentioned by Deepak as well, that there are certain agreements with the partners in terms of stock replenishment and this systematically will continue to give kind of fluctuation for 2026 I think."
Diabetes Franchise: Defending Share in a Shifting Market
- Lantus resilience: Maintained 31% market leadership in the basal insulin segment with volume acceleration of plus 6%, despite turbulence in the insulin market and GLP-1 encroachment. Management denied any disruption in Lantus availability in urban Maharashtra, calling any reported issue a one-off stock distribution matter.
- Toujeo momentum: The preferred second-generation basal insulin grew in double digits and is now expanding into the public sector, which management flagged as a new growth vector.
- Soliqua's three-segment play: Soliqua targets patients not controlled on basal insulin, patients not controlled on OADs, and patients requiring stricter control on premix. Its differentiation is weight neutrality with better glycemic control and very low or no hypoglycemia.
- Analog market tailwind: Novo Nordisk's discontinuation of pen versions of human insulin moved patients from human to analog, and Sanofi was party to that shift. Toujeo and Soliqua drove double-digit growth, while Lantus contributed single good digit growth.
- Soliqua study milestone: The last patient was enrolled on 12 December 2025 in a 105-patient, 9-site Indian study evaluating safety and efficacy in obese adults with uncontrolled Type 2 diabetes. Publication is awaited.
- Reusable pen project: India is a pioneer market for a Soliqua cartridge/reusable pen, favored by the group for environmental reasons. The project is in progress but has no firm timeline: management said "I hope that it will happen in the next upcoming years" and is still working on the business case.
Deepak Arora: "Soliqua has unique USPs basically controlling not only diabetes, but also... with insulin usage, there is an increase in the weight. Soliqua provides weight neutrality with better control. So that's a unique feature what Soliqua brings in with very low or no hypoglycemia."
Profitability: Margin Compression Without Segment Disclosure
- EBITDA margin at an 8-quarter low: The quarter's EBITDA margin fell to 21.5%, driven by the partnership revenue drop and a decline in other operating income related to the cessation of certain promotion services to the private company after signing the partnership.
- Operating expense reduction masks the story: Operating expenses fell 17% in the quarter and full year, reflecting the strategy of signing contracts with different partners. But the top-line impact from partnership phasing overwhelmed the cost savings.
- Full-year PBT held up: Profit before tax rose 1% for the full year despite transformation impacts, and profit after tax rose 4%. Management characterizes the quarter's performance as phasing-driven, not structural.
- Segment margins are a black box: When asked for segment-level margin details to explain the compression, management declined: "we are not allowed to give the details by business, let's say, between diabetes and partnership in terms of margin."
- Export drag was anticipated: The significant drop in exports reflects the divestment of the Ankleshwar site with Zentiva in 2021. Sanofi continued selling for Zentiva until 2024, when Zentiva received Indian authorization to commercialize the product directly. This was previously communicated.
Strategy & Portfolio Boundaries
- No new products in 2026: Management confirmed there are no new product launches for Sanofi India this year. Growth must come from existing brands, public-sector expansion, and partnership stabilization.
- Therapy area focus is locked: The strategy is to focus on diabetes, insulin, cardiovascular, and CNS. Diversifying into other areas is not seen as synergistic with the current portfolio or team, and the group strategy reinforces this narrow mandate.
- No plan to combine listed and private entities: Management evaluated bringing all operating companies in India under single legal ownership but concluded it would not bring value for shareholders.
- Pipeline exists but is distant: Phase II and Phase III studies are ongoing with teplizumab (Teizeild), Brivekimig, and Frexalimab. The LANDMARC study concluded with 382 sites and nearly 6,000 patients, with more publications expected this year and at IDF next year.
- CSR and digital initiatives: The company is bringing a novel pen to market combined with AI-enabled digital solutions for better adherence and diabetes management. CSR outreach has expanded.
Rachid Ayari: "So based on the group strategy as well so we want to focus on certain therapeutic areas and not to expand. If there is opportunity, yes. But for now, the strategy for the listed company is to focus mainly on diabetes insulin... But diversifying today to another area, we don't see that there will be a synergy with the current portfolio with the current team."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Partnership stabilization | Fluctuation will continue through 2026; stabilization expected once stock replenishment agreements normalize | By end of 2026 |
| Partnership growth | Partnership expected to grow, but with quarter-to-quarter fluctuation persisting | Through 2026 |
| Institutional business fix | Innovative access model to tackle aggressive competition discount | As we get into 2026 |
| Soliqua public-sector entry | Soliqua entering the public sector | New, no specific date |
| Toujeo public-sector expansion | Toujeo expansion in the public sector | New, no specific date |
| Final dividend | Final dividend to be approved at general assembly | May/June of this year |
| New publications | Real-world evidence from LANDMARC and Soliqua real-world study | This year / IDF next year |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Revenue (domestic net sales, full year) | ₹1,511 cr, diabetes ~half, partnership ~half |
| Diabetes segment growth (Q3) | 11%, double-digit growth |
| Partnership segment growth (full year) | -2% vs last year, stabilizing |
| Partnership sales (Q3) | ~₹200 cr (per an analyst's math) |
| Partnership sales (Q4) | ₹153 cr, impacted by phasing, stock replenishment, frozen periods, and gross-to-net for OADs |
| Operating expenses | -17% YoY in the quarter and full year, reflecting partnership strategy |
| Profit before tax (full year) | +1%, significant drop in the quarter due to phasing and top-line stock movement |
| Profit before exceptional items (full year) | +1% |
| Profit after tax (full year) | +4% |
| EBITDA margin | 21.5%, an 8-quarter low, impacted by phasing |
| Export | Significant drop in the quarter and full year, related to Ankleshwar site divestment |
| Lantus market share (basal segment) | 31% leadership, volume acceleration of +6% |
| Toujeo growth | Double digits |
| Soliqua growth | Double digits |
| Overall analog market growth | +6% |
| Partnership volume growth (excl. cert effect) | +4% |
| IQVIA growth for Emcure portfolio (cardio and OAD) | +5% |
| Soliqua real-world study enrollment | 105 patients across 9 sites in India, last patient in 12 Dec 2025 |